Related Experiment Videos
Comparison of clinical pharmacology of voriconazole and posaconazole
Beata M Sienkiewicz1, Łukasz Łapiński1, Anna Wiela-Hojeńska1
1Wroclaw Medical University, Wroclaw, Poland.
Abstract:
Despite greater knowledge and possibilities in pharmacotherapy, fungal infections remain a challenge for clinicians. As the population of immunocompromised patients and those treated for their hematologic ailments increases, the number of fungal infections grows too. This is why there is still a quest for new antifungal drugs as well as for optimization of pharmacotherapy with already registered pharmaceutics. Voriconazole and posaconazole are broad-spectrum, new generation, triazole antifungal agents. The drugs are used in the pharmacotherapy of invasive aspergillosis, Candida and Fusarium infections. Voriconazole is also used in infections caused by Scedosporium. Posaconazole is used in the treatment of coccidioidomycosis and chromoblastomycosis. Besides some similarities, the two mentioned drugs also show differences in therapeutic indications, pharmacokinetics (mainly absorption and metabolism), frequency and severity of adverse drug reactions, drug-drug interactions and dosage. As both of the drugs are used in the treatment of invasive fungal infections in adults and children, detailed knowledge of the clinical pharmacology of antifungal agents is the main factor in pharmacotherapy optimization in treatment of fungal infections. The goal of the article is to present and compare the clinical pharmacology of voriconazole and posaconazole as well as to point out the indications and contraindications of using the drugs, determine factors influencing their pharmacotherapy, and provide information that might be helpful in the treatment of fungal infections.
Insights
Voriconazole and posaconazole are effective antifungal drugs, but differ in usage, absorption, metabolism, side effects, and interactions. Understanding their clinical pharmacology optimizes treatment for invasive fungal infections in all patients.
Area of Science:
- Medical Mycology
- Clinical Pharmacology
- Infectious Diseases
Background:
- Fungal infections pose a significant clinical challenge, particularly in immunocompromised and hematologic patients.
- The increasing prevalence necessitates the development of new antifungal agents and optimization of existing therapies.
- Voriconazole and posaconazole represent advanced broad-spectrum triazole antifungals.
Purpose of the Study:
- To compare the clinical pharmacology of voriconazole and posaconazole.
- To detail their therapeutic indications, contraindications, and pharmacokinetic profiles.
- To provide insights for optimizing antifungal pharmacotherapy.
Main Methods:
- Comparative analysis of clinical pharmacology data for voriconazole and posaconazole.
- Review of therapeutic indications, adverse drug reactions, drug-drug interactions, and dosage regimens.
- Literature synthesis on factors influencing pharmacotherapy.
Main Results:
- Voriconazole and posaconazole exhibit distinct profiles in absorption, metabolism, adverse effects, and drug interactions.
- Specific indications vary, with voriconazole used for Scedosporium and posaconazole for coccidioidomycosis and chromoblastomycosis.
- Both agents are crucial for treating invasive aspergillosis and Candida infections.
Conclusions:
- Detailed knowledge of voriconazole and posaconazole clinical pharmacology is essential for effective treatment of invasive fungal infections.
- Understanding drug-specific differences allows for optimized pharmacotherapy selection and management.
- This comparative analysis aids clinicians in treating diverse fungal infections in adult and pediatric populations.